ArticleSkin health and disease2025
Extracorporeal photopheresis for pembrolizumab-induced dermatitis: a case report.
Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-related adverse events (irAE) are common in checkpoint blockade-treated patients and limit its clinical application. Corticosteroids are the first-line therapy for treatment of irAE, but animal models clearly demonstrate that steroids diminish anti-programmed cell death protein 1 (PD-1)-induced tumour immunity. Better strategies to manage irAE while preserving anti-tumour immunity are needed. Extracorporeal photopheresis (ECP) was recently introduced as second-line treatment for steroid-refractory immune checkpoint inhibitor (ICI)-related colitis and hepatitis. Here, we extend the application of ECP to immune-related maculopapular rash after adjuvant anti-PD-1 therapy in a single melanoma patient. The patient's dermatitis markedly improved after off-label ECP, with a substantial reduction in skin lesions and pruritus scores, and stabilization of immune markers. The patient remained well after ECP with no recurrent or metastatic disease at 14 months after starting ECP treatment. Hence, in this case, ECP led to successful resolution of pembrolizumab-induced dermatitis and a favourable oncological outcome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.